These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 35746673)

  • 21. Cabotegravir/Rilpivirine: the last FDA-approved drug to treat HIV.
    Taki E; Soleimani F; Asadi A; Ghahramanpour H; Namvar A; Heidary M
    Expert Rev Anti Infect Ther; 2022 Aug; 20(8):1135-1147. PubMed ID: 35596583
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Formulation and pharmacology of long-acting rilpivirine.
    Williams PE; Crauwels HM; Basstanie ED
    Curr Opin HIV AIDS; 2015 Jul; 10(4):233-8. PubMed ID: 26049947
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacokinetics of nucleoside/nucleotide reverse transcriptase inhibitors for the treatment and prevention of HIV infection.
    Wonganan P; Limpanasithikul W; Jianmongkol S; Kerr SJ; Ruxrungtham K
    Expert Opin Drug Metab Toxicol; 2020 Jul; 16(7):551-564. PubMed ID: 32508203
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacokinetics and antiviral activity of cabotegravir and rilpivirine in cerebrospinal fluid following long-acting injectable administration in HIV-infected adults.
    Letendre SL; Mills A; Hagins D; Swindells S; Felizarta F; Devente J; Bettacchi C; Lou Y; Ford S; Sutton K; Shaik JS; Crauwels H; D'Amico R; Patel P
    J Antimicrob Chemother; 2020 Mar; 75(3):648-655. PubMed ID: 31873746
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-acting antiretrovirals: a new era for the management and prevention of HIV infection.
    Thoueille P; Choong E; Cavassini M; Buclin T; Decosterd LA
    J Antimicrob Chemother; 2022 Feb; 77(2):290-302. PubMed ID: 34499731
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The role of rilpivirine in clinical practice: strengths and weaknesses of the new nonnucleoside reverse transcriptase inhibitor for HIV therapy.
    Imaz A; Podzamczer D
    AIDS Rev; 2012; 14(4):268-78. PubMed ID: 23258301
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Low Frequency of Drug-Resistant Variants Selected by Long-Acting Rilpivirine in Macaques Infected with Simian Immunodeficiency Virus Containing HIV-1 Reverse Transcriptase.
    Melody K; McBeth S; Kline C; Kashuba AD; Mellors JW; Ambrose Z
    Antimicrob Agents Chemother; 2015 Dec; 59(12):7762-70. PubMed ID: 26438501
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Emergence of dual antiretroviral therapy as a viable regimen option for the treatment of patients with HIV infection.
    Fida M; Mahmood M; Temesgen Z
    Drugs Today (Barc); 2020 Jun; 56(6):405-421. PubMed ID: 32525138
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-Acting Injectable Cabotegravir + Rilpivirine for HIV Maintenance Therapy: Week 48 Pooled Analysis of Phase 3 ATLAS and FLAIR Trials.
    Rizzardini G; Overton ET; Orkin C; Swindells S; Arasteh K; Górgolas Hernández-Mora M; Pokrovsky V; Girard PM; Oka S; Andrade-Villanueva JF; Richmond GJ; Baumgarten A; Masiá M; Latiff G; Griffith S; Harrington CM; Hudson KJ; St Clair M; Talarico CL; Patel P; Cutrell A; Van Eygen V; D'Amico R; Mrus JM; Wu S; Ford SL; Chow K; Roberts J; Wills A; Walters N; Vanveggel S; Van Solingen-Ristea R; Crauwels H; Smith KY; Spreen WR; Margolis DA
    J Acquir Immune Defic Syndr; 2020 Dec; 85(4):498-506. PubMed ID: 33136751
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy, safety, and tolerability of switching to long-acting cabotegravir plus rilpivirine versus continuing fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed adults with HIV, 12-month results (SOLAR): a randomised, open-label, phase 3b, non-inferiority trial.
    Ramgopal MN; Castagna A; Cazanave C; Diaz-Brito V; Dretler R; Oka S; Osiyemi O; Walmsley S; Sims J; Di Perri G; Sutton K; Sutherland-Phillips D; Berni A; Latham CL; Zhang F; D'Amico R; Pascual Bernáldez M; Van Solingen-Ristea R; Van Eygen V; Patel P; Chounta V; Spreen WR; Garges HP; Smith K; van Wyk J
    Lancet HIV; 2023 Sep; 10(9):e566-e577. PubMed ID: 37567205
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Retrospective study on the outcome of two-drug regimens based on dolutegravir plus one reverse transcriptase inhibitor in virologically-suppressed HIV-infected patients.
    Galizzi N; Poli A; Galli L; Muccini C; Mastrangelo A; Dell'Acqua R; Maillard M; Bossolasco S; Cinque P; Lazzarin A; Castagna A; Gianotti N
    Int J Antimicrob Agents; 2020 Mar; 55(3):105893. PubMed ID: 31926287
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The future of long-acting cabotegravir plus rilpivirine therapy: deeds and misconceptions.
    Rusconi S; Santoro MM; Capetti AF; Gianotti N; Zazzi M
    Int J Antimicrob Agents; 2022 Sep; 60(3):106627. PubMed ID: 35760225
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-acting antiviral agents for HIV treatment.
    Margolis DA; Boffito M
    Curr Opin HIV AIDS; 2015 Jul; 10(4):246-52. PubMed ID: 26049949
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comprehensive database of HIV mutations selected during antiretroviral in vitro passage experiments.
    Tao K; Zhou J; Nagarajan P; Tzou PL; Shafer RW
    Antiviral Res; 2024 Oct; 230():105988. PubMed ID: 39154752
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Contribution of cabotegravir + rilpivirine long-acting for the treatment of HIV-1 infection.
    Calleja-Hernández MÁ; Martinez-Sesmero JM; Vallejo-Aparicio LA; Hernández-Novoa B; Badia X
    Farm Hosp; 2022 Jul; 46(4):208-214. PubMed ID: 36183218
    [TBL] [Abstract][Full Text] [Related]  

  • 36. M184I/V substitutions and E138K/M184I/V double substitutions in HIV reverse transcriptase do not significantly affect the antiviral activity of EFdA.
    Oliveira M; Brenner BG; Xu H; Ibanescu RI; Mesplède T; Wainberg MA
    J Antimicrob Chemother; 2017 Nov; 72(11):3008-3011. PubMed ID: 28961903
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Doravirine responses to HIV-1 viruses bearing mutations to NRTIs and NNRTIs under in vitro selective drug pressure.
    Brenner BG; Oliveira M; Ibanescu RI; Routy JP; Thomas R
    J Antimicrob Chemother; 2023 Aug; 78(8):1921-1928. PubMed ID: 37303226
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Predictors of clinically significant drug-drug interactions among patients treated with nonnucleoside reverse transcriptase inhibitor-, protease inhibitor-, and raltegravir-based antiretroviral regimens.
    Patel N; Abdelsayed S; Veve M; Miller CD
    Ann Pharmacother; 2011 Mar; 45(3):317-24. PubMed ID: 21386025
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dynamics of Rilpivirine Resistance-Associated Mutation: E138 in Reverse Transcriptase among Antiretroviral-Naive HIV-1-Infected Individuals in Turkey.
    Sayan M; Sultanoglu N; Sanlidag T
    AIDS Res Hum Retroviruses; 2023 Feb; 39(2):84-90. PubMed ID: 36301912
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Virological Failure After Switch to Long-Acting Cabotegravir and Rilpivirine Injectable Therapy: An In-depth Analysis.
    van Welzen BJ; Van Lelyveld SFL; Ter Beest G; Gisolf JH; Geerlings SE; Prins JM; Van Twillert G; Van Nieuwkoop C; Van der Valk M; Burger D; Wensing AMJ
    Clin Infect Dis; 2024 Jul; 79(1):189-195. PubMed ID: 38207125
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.